

Notice of 7th Annual General Meeting

NOTICE is hereby given that the Seventh Annual General Meeting of the Members of **Cohance Lifesciences Limited** (Formerly, Suven Pharmaceuticals Limited) will be held on **Friday, the 19th day of September, 2025 at 2:30 p.m. IST** through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM"), to transact the following businesses:

ORDINARY BUSINESS

Item No. 1 – Adoption of financial statements

To consider and adopt the audited standalone and consolidated financial statements of the Company for the financial year ended March 31, 2025 together with the reports of the Board of Directors and the Auditor's thereon.

"RESOLVED THAT the audited standalone financial statements of the Company for the financial year ended March 31, 2025, together with the reports of the Board of Directors and of the Auditors thereon, be and are hereby received, considered and adopted;

RESOLVED FURTHER THAT the audited consolidated financial statements of the Company for the financial year ended March 31, 2025, together with the report of Auditors thereon, be and are hereby received, considered and adopted."

Item No. 2 –Re-appointment of Dr. V. Prasada Raju, a Director liable to retire by rotation

To re-appoint Dr. V. Prasada Raju (DIN: 07267366), who retires by rotation, and being eligible, offers himself for re-appointment.

"RESOLVED THAT pursuant to the provisions of Section 152 of the Companies Act, 2013, Dr. V. Prasada Raju, (DIN: 07267366), who retires by rotation at 7th Annual General Meeting and being eligible, has offered himself for re-appointment, be and is hereby appointed as a Director of the Company, liable to retire by rotation."

SPECIAL BUSINESS

Item No. 3 – Approval for payment of Remuneration to Dr. V Prasada Raju (DIN: 07267366), Managing Director of the Company

To consider and if thought fit, to pass, the following resolution as an ordinary resolution:

"RESOLVED THAT pursuant to Sections 196, 197, 203 and other applicable provisions of the Companies Act, 2013 and the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and other applicable provisions (including any statutory modification or re-enactment thereof for the time being in force) and pursuant to the recommendation of Nomination and Remuneration Committee and approval of Board of Directors ("Board"), consent of the members be and is hereby accorded for payment of remuneration, as morefully described in the Explanatory Statement annexed to this Notice of the 7th Annual General meeting ("AGM"), to Dr. V Prasada Raju (DIN: 07267366), who was appointed as Managing Director of the Company with effect from September 29, 2023, for the remaining term of his office as the Managing Director of the Company as approved by the members of the Company at the 5th AGM, with liberty to the Board (which term shall be deemed to include the Nomination and Remuneration Committee of the Board) to alter and vary the terms and conditions including remuneration, as it may deem fit, subject to compliance of the applicable laws;

RESOLVED FURTHER THAT the Board be and is hereby authorized to do all such acts, matters, deeds, things as it may deem fit, as it may in its absolute discretion deem necessary, proper or desirable, including but not limited to delegating severally all or any of the powers conferred on it or under this resolution to any Committee(s) of the Board, any Director(s) or any other Officer(s) of the Company, as may be considered necessary or expedient to give effect to this resolution and to settle any question, difficulty or doubt that may arise in respect of aforesaid, without being required to seek any further consent or approval of members of the Company, or otherwise to the end and intent that they shall be deemed to have given their approval thereto expressly by the authority of this resolution."

Item No. 4 - Appointment of Secretarial Auditors of the Company

To consider and, if thought fit, to pass the following resolution as an Ordinary Resolution:

RESOLVED THAT pursuant to the provisions of Sections 179 and 204 and other applicable provisions of the Companies Act,

2013, read with the rules made thereunder, and Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, and based on the recommendations of the Audit Committee and the Board of Directors, the approval of the members, be and is hereby accorded for the appointment of M/s Makarand M. Joshi & Co., Company Secretaries (Firm registration no: P2009MH007000), as Secretarial Auditors of the Company for a term of five consecutive years, commencing from the financial year 2025-26 till financial year 2029-30, at such remuneration and on such terms and conditions, as may be determined by the Board of

Directors (including its committees thereof), and to avail any other services, certificates, or reports as may be permissible under applicable laws;

RESOLVED FURTHER THAT the Board of Directors of the Company (including its committees thereof), be and is hereby authorized to do all such acts, deeds, matters and things as may be deemed proper, necessary, or expedient, for the purpose of giving effect to this resolution and for matters connected therewith, or incidental thereto.

Date: June 26, 2025

Place: Hyderabad

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai-400093, Maharashtra, India

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India

CIN: L24299MH2018PLC422236

Email: investorservices@suvenpharm.com

Website: <https://www.suvenpharm.com>

By order of the Board of Directors
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Sd/-
Kundan Kumar Jha
Company Secretary, Compliance Officer
and Head - Legal
Membership No. A17612

NOTES FOR MEMBERS' ATTENTION:

1. The explanatory statement pursuant to Section 102 of the Companies Act, 2013 ("Act") and the Rules made thereunder, Secretarial Standard on General Meetings ("SS-2") and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") wherever applicable, in respect of the special business set out in the Notice, is annexed hereto. The Board of Directors of the Company at its meeting held on June 26, 2025, has considered and recommended to include item nos. 3 and 4, of the special business in the Notice for seeking approval of the members at the 7th Annual General Meeting ("AGM") of the Company.
2. The Ministry of Corporate Affairs, Government of India ("MCA"), and the Securities and Exchange Board of India ("SEBI"), allowed companies to conduct Annual General Meeting ("AGM") through video conference ("VC")/ other audio-visual means ("OAVM"), without the physical presence of Members at a common venue. Pursuant to General Circular Nos. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, 20/2020 dated May 5, 2022, 09/2024 dated September 19, 2024, and other circulars issued by the Ministry of Corporate Affairs ('MCA') and the SEBI Circular Nos. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 and SEBI/HO/CFD/CFD-PoD-2/P/CIR/2024/133 dated October 3, 2024, respectively (collectively referred to as 'Circulars'), companies are permitted to hold the AGM through VC/ OAVM, without the physical presence of the members at a common venue. Accordingly, the 7th AGM of the Company will be convened through VC/ OAVM in compliance with the provisions of the Act and Rules made thereunder, the SEBI Listing Regulations read with the aforesaid Circulars. The deemed venue for the 7th AGM shall be at the Registered Office of the Company.
3. In line with the Circulars, the Company is providing VC/ OAVM facility to its members to attend the 7th AGM. For this purpose, the Company has entered into an agreement with KFin Technologies Limited ("KFINTECH"), as the authorized agency for facilitating voting through electronic means. The facility of casting votes by a Member using remote e-voting system as well as e-voting on the date of the AGM will be provided by KFINTECH.
4. Since the AGM will be held through VC/ OAVM, the Route Map of the venue of the Meeting is not annexed hereto. Since this AGM is being held pursuant to the said Circulars through VC / OAVM, physical attendance of Members has been dispensed with. Accordingly, the facility for appointment of proxies by the Members will not be available for the 7th AGM and hence, the Proxy Form and Attendance Slip are not annexed to this Notice.
5. The facility for attending the AGM virtually will be made available for 1,000 members on first come first served basis. This will not include large members (i.e. members with 2% or more shareholding), Promoters, institutional investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders' Relationship Committee, Auditors, etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
6. The VC/ OAVM facility for members to join the meeting, shall be kept open for 30 minutes before the start of the 7th AGM and will be closed on expiry of 30 minutes after closure of the 7th AGM. Members can attend the 7th AGM through VC/ OAVM by following the instructions mentioned in this Notice.
7. Corporate members whose authorized representatives are intending to attend the meeting are requested to send a certified copy of the Board resolution authorizing such representative to attend the 7th AGM through VC/ OAVM and cast their votes through e-voting. Such documents can be sent to prenukaacs@gmail.com, with a copy marked to investorservices@suvenpharm.com.
8. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/ JPG Format) of the relevant Board Resolution/ Authority letter, etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail at prenukaacs@gmail.com, with a copy marked to investorservices@suvenpharm.com.
9. Members attending the 7th AGM through VC/ OAVM shall be counted for the purpose of reckoning the quorum under Section 103 of the Act.
10. In case of joint holders attending the Meeting, only such joint holder who is higher in the order of names will be entitled to vote at the AGM.
11. The statutory registers including Register of Directors and Key Managerial Personnel and their shareholding, the Register of Contracts or Arrangements in which Directors are interested, maintained under the Act and the

Certificate from the Secretarial Auditors of the Company certifying that the ESOP Scheme of the Company are being implemented in accordance with the SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021, will be available for inspection by the members during the 7th AGM. The documents referred to in the Notice and Explanatory Statement will be available for inspection in electronic mode from the date of circulation of this Notice up to the date of the 7th AGM. Members who wish to inspect the register are requested to write to the Company by sending e-mail to investorservices@suvenpharm.com.

12. In accordance with the aforesaid Circulars, the Notice of the 7th AGM along with the Annual Report for the financial year ended March 31, 2025 has been sent only through electronic mode to the members who have registered their e-mail addresses with the Company/ Depository Participants/ Company's Registrar and Transfer Agent ("RTA"). The Notice of 7th AGM and Annual Report are also available on the Company's website at <https://www.suvenpharm.com>, on the website of the Stock Exchanges, i.e. BSE Limited ("BSE") at www.bseindia.com and National Stock Exchange of India Limited ("NSE") at www.nseindia.com. Physical copy of the Notice of the 7th AGM and the Annual Report for the year ended March 31, 2025 has not been sent to the members.
13. In accordance with the Circulars, members who have not registered their e-mail address may register their e-mail address on <https://ris.kfintech.com/default.aspx#> or with their Depository Participant or send their request at investorservices@suvenpharm.com along with their Folio No./ DP ID and Client ID and valid e-mail address for registration.
14. Pursuant to Section 108 of the Act, read with Rule 20 of the Companies (Management and Administration) Rules, 2014, as amended from time to time, Regulation 44 of the SEBI Listing Regulations and the aforesaid Circulars, the Company is pleased to offer voting by electronic means to the members to cast their votes electronically on all resolutions set forth in this Notice. The detailed instructions for e-voting and attending the 7th AGM through VC/ OAVM are given as an attachment to this Notice.
15. In terms of Schedule I of the SEBI Listing Regulations, listed companies are required to use the Reserve Bank of India's approved electronic mode of payment such as electronic clearance service (ECS), LECS (Local ECS)/ RECS (Regional ECS)/ NECS (National ECS), direct credit, real time gross settlement, national electronic fund transfer (NEFT), etc. for making payments like dividend etc. to the members. Accordingly, members holding securities in demat mode are requested to update their bank details with their Depository Participants. Members holding securities in physical form shall send a request updating their bank details, to the Company's RTA.
16. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, Permanent Account Number (PAN), mandates, nominations, power of attorney, bank details such as, name of the bank and branch details, bank account number, MICR code, IFSC code, etc.
 - a. **For shares held in electronic form:** Members holding shares in electronic form are requested to submit their request to their Depository Participants with whom they are maintaining their demat accounts.
 - b. **For shares held in physical form:** SEBI vide its Circular dated November 3, 2021 and SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024 has mandated registration of PAN, KYC details and Nomination, by holders of physical securities. Members holding shares in physical form can submit their PAN, KYC details (i.e. postal address with pin code, email address, mobile number, bank account details) and Nomination details by holders through duly filled and signed Form ISR-1 to the Company / KFin Technologies Limited, at Selenium, Tower B, Plot 31-32, Gachibowli, Financial District, Nanakramguda, Hyderabad – 500032 or by email to einward.ris@kfintech.com from their registered email id. It may be noted that any service request or compliant can be processed only after the folio is KYC compliant.
17. Members seeking any information with regard to the accounts or any matter to be placed at the 7th AGM, are requested to write to the Company **on or before Friday, September 12, 2025** through email on investorservices@suvenpharm.com. The same will be replied by the Company suitably.
18. In accordance with the provisions of Section 72 of the Act, Members can avail the facility of nomination in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13 to RTA. If a Member desires to opt out or cancel the earlier nomination and

record a fresh nomination, he/she may submit the same in Form No. SH-14 or Form ISR-3, as the case may be, to RTA. The aforementioned forms are available on the Company's website at <https://suvenpharm.com/corporate-info/> and on the website of Kfin Technologies Limited at <https://ris.kfintech.com/clientservices/isc/isrforms.aspx>. In case of shares held in dematerialized form, the nomination/change in nomination should be lodged with their respective DPs.

19. Pursuant to Regulation 40(1) of the SEBI Listing Regulations, as amended, mandates that transfer, transmission and transposition of securities of listed companies held in physical form shall be effected only in demat mode. Further, SEBI, vide its Circular dated 25th January, 2022, has clarified that listed companies, with immediate effect, shall issue the securities only in demat mode while processing investor service requests pertaining to issuance of duplicate shares, exchange of shares, endorsement, sub-division/ consolidation of share certificates, etc. In view of this as also to eliminate all risks associated with physical shares and for ease of portfolio management, Members holding shares in physical form are requested to consider converting their holdings to demat mode. Accordingly, Members are requested to make service requests by submitting a duly filled and signed Form ISR – 4, the format of which is available on the Company's website at <https://suvenpharm.com/corporate-info/#SRSsec> and on the website of the Company's Registrar and Transfer Agents, KFin Technologies Limited at <https://ris.kfintech.com/clientservices/isc/isrforms.aspx>. It may be noted that any service request can be processed only after the folio is KYC Compliant.

20. SEBI vide Circular Nos. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/131 dated July 31, 2023, and SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/135 dated August 4, 2023, read with Master Circular No. SEBI/HO/OIAE/OIAE_IAD-1/P/CIR/2023/145 dated July 31, 2023 (updated as on August 11, 2023), has established a common Online Dispute Resolution Portal ("ODR Portal") for resolution of disputes arising in the Indian Securities Market.

Pursuant to above-mentioned circulars, post exhausting the option to resolve their grievances with the RTA/ Company directly and through existing SCORES platform, the investors can initiate dispute resolution through the ODR Portal (<https://smartodr.in/login>).

21. KFin Technologies Limited, Registrar and Share Transfer Agent ("RTA") of the Company has launched a unified platform "KPRISM" for the benefit of shareholders. KPRISM is a self-service portal can be accessed at [https://ris.kfintech.com/default.aspx#>Investor Services > Investor Support](https://ris.kfintech.com/default.aspx#>Investor%20Services%20Investor%20Support), that enables the shareholders to access their portfolios serviced by KFIN, and check details like dividend status and make request for annual reports, change of address, update bank mandate, download standard forms, etc.

Members are requested to register / signup, using the Name, PAN, Mobile and email ID. Post registration, user can login via OTP and execute activities like, raising Service Request, Query, Complaints, check for status, KYC details, Dividend, Interest, Redemptions, e-Meeting and e-Voting details. Quick link to access the signup page: <https://kprism.kfintech.com/signup>

22. SEBI vide its Circular No. SEBI/HO/MIRSD/MIRSD-PoD-1/P/CIR/2023/37 March 16, 2023 (subsequently referred in Master Circular no. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024) has mandated that with effect from April 1, 2024, dividend to security holders (holding securities in physical form), shall be paid only through electronic mode. Such payment shall be made only after furnishing the PAN, choice of nomination, contact details including mobile number, bank account details and specimen signature.

23. **To support the "Green Initiative", Members who have not registered their e-mail addresses so far are requested to register same with their DPs in case the shares are held by them in electronic form and with Kfin Tech in case the shares are held by them in physical form for receiving all communications including Annual Report, Notices, Circular, etc. from the Company in electronic mode.**

24. **Unclaimed Dividends/ Transfer to Investor Education and Protection Fund:**

Members are requested to note that, dividends if not encashed for a consecutive period of 7 years from the date of transfer to Unpaid Dividend Account of the Company, are liable to be transferred to the Investor Education and Protection Fund ("IEPF"). The shares in respect of such unclaimed dividends are also liable to be transferred to the demat account of the IEPF Authority. In view of this, Members are requested to claim their dividends from the Company, within the stipulated timeline.

25. Information and Instructions for joining the AGM through VC/ OAVM and e-voting are as follows:

A. PROCEDURE FOR JOINING THE AGM THROUGH VC / OAVM:

The Company will provide VC / OAVM facility to its Members for participating at the AGM.

- i) Members will be able to attend the AGM through VC / OAVM or view the live webcast at <https://emeetings.kfintech.com> by using their e-voting login credentials and selecting the 'EVENT' for the Company's AGM. Further Members can also use the OTP based login for logging in

Members are requested to follow the procedure given below:

- i) Launch internet browser (chrome/firefox/safari) by typing the URL: <https://emeetings.kfintech.com>
- ii) Enter the login credentials (i.e., User ID and password for e-voting).
- iii) After logging in, click on "Video Conference" option
- iv) Then click on camera icon appearing against AGM event of Cohance Lifesciences Limited, to attend the Meeting.
- ii) Members who do not have User ID and Password for e-voting or have forgotten the User ID and Password may retrieve the same by following the procedure given in the E-voting instructions.
- iii) Members may join the AGM through Laptops, Smartphones, Tablets or iPads for better experience. Further, Members will be required to use internet with a good speed to avoid any disturbance during the AGM. Members will need the latest version of Chrome, Safari, Internet Explorer 11, MS Edge or Mozilla Firefox.
- iv) Please note that participants connecting from Mobile Devices or Tablets or through Laptops connecting via mobile hotspot may experience Audio / Video loss due to fluctuation in their respective network. It is therefore

recommended to use stable Wi-Fi or LAN connection to mitigate any glitches. Members will be required to grant access to the web-cam to enable two-way video conferencing.

- v) Facility to join the Meeting will be opened 30 (thirty) minutes before the scheduled time of the AGM and will be kept open throughout the proceedings of the AGM.
- vi) Members who would like to express their views or ask questions during the AGM may register themselves as speakers by logging on to <https://emeetings.kfintech.com> and clicking on the 'Speaker Registration' option available on the screen after login. The Speaker Registration will be open during **Monday, September 15, 2025 to Wednesday, September 17, 2025**. Only those members who are registered as speakers will be allowed to express their views or ask questions. The Company reserves the right to restrict the number of questions and number of speakers, depending upon availability of time as appropriate for smooth conduct of the AGM.
- vii) Alternatively, members may also visit <https://emeetings.kfintech.com> and click on the tab 'Post Your Queries' and post their queries/ views/questions in the window provided, by mentioning their name, demat account number/folio number, email ID and mobile number. The window will be closed on **Wednesday, September 17, 2025 (5.00 p.m. IST)**.
- viii) Members who need assistance before or during the AGM, can contact KFinTech on emeetings@kfintech.com or call on toll free numbers 1800-309-4001. Kindly quote your name, DP ID-Client ID / Folio no. and E-voting Event Number in all your communications.

B. PROCEDURE FOR REMOTE E-VOTING AND E-VOTING AT THE AGM:

- i) Pursuant to the provisions of Section 108 of Companies Act, 2013 read with Rule 20 of Companies (Management and Administration) Rules, 2014, as amended from time to time, and Regulation 44 of the SEBI Listing Regulations, the Company is providing to its members

the facility to exercise their right to vote on the resolutions proposed to be passed in the Seventh Annual General Meeting (AGM) by electronic means ("e-voting") and the business may be transacted through e-voting facility. The members may cast their votes remotely, using an electronic voting system from a place other than the venue of the Meeting ("remote e-voting")

Further, the facility for voting through electronic voting system will also be made available at the

Meeting ("Insta Poll") and members attending the Meeting who have not cast their vote(s) by remote e-voting will be able to vote at the Meeting through Insta Poll.

- ii) The Company has engaged the services of KFINTECH as the agency to provide e-voting facility. The manner of voting remotely by members holding shares in dematerialized mode, physical mode and for members who have not registered their email addresses is provided in the instructions given below.

- iii) The remote e-voting facility will be available during the following voting period:

| EVEN | Date of 7 th AGM | Cut-off date for remote e-voting/ insta poll | Commencement of remote e-voting | End of remote e-voting |
|------|---|--|--|--|
| 9096 | Friday, September 19, 2025 at 2:30 p.m. IST | Friday, September 12, 2025 | Monday, September 15, 2025, at 9:00 a.m. IST | Thursday, September 18, 2025, at 5:00 p.m. IST |

- iv) The remote e-voting will not be allowed beyond the aforesaid date and time and the remote e-voting module shall be forthwith disabled by KFinTech upon expiry of the aforesaid period. During the e-voting period, shareholders of the company, holding shares either in physical form or in dematerialised form, as on the **cut-off date being September 12, 2025** only shall be entitled to avail the facility of remote e-voting / Insta Poll.
- v) The members who have cast their vote by remote e-voting prior to the AGM may also attend/ participate in the AGM through VC/ OAVM but shall not be entitled to cast their vote again.

by both modes, then voting done through remote e-voting shall prevail and vote(s) cast at the Meeting shall be treated as "INVALID".

- c) A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date, i.e. September 12, 2025 only shall be entitled to avail the facility of remote e-voting or for participation at the AGM and voting through Insta Poll. A person who is not a member as on the cutoff date, should treat the Notice for information purpose only.
- d) The Company has opted to provide the same electronic voting system at the Meeting, as used during remote e-voting, and the said facility shall be operational till all the resolutions proposed in the Notice are considered and voted upon at the Meeting and may be used for voting only by the members holding shares as on the cutoff date who are attending the Meeting and who have not already cast their vote(s) through remote e-voting.

Information and instructions relating to e-voting are as under:

- a) The members who have cast their vote(s) by remote e-voting may also attend the Meeting but shall not be entitled to cast their vote(s) again at the Meeting. Once the vote on a resolution is cast by a member, whether partially or otherwise, the member shall not be allowed to change it subsequently or cast the vote again.
- b) A member can opt for only single mode of voting per EVEN, i.e., through remote e-voting or voting at the Meeting (Insta Poll). If a member casts vote(s)

For Non-Individual Shareholders holding shares in demat mode AND Shareholders holding shares in physical form:

- A. In case a Member receives an e-mail from KFinTech [for Members whose e-mail IDs are registered with the Company/Depository Participant(s)]:**

- i) Launch internet browser by typing the URL: <https://evoting.kfintech.com>.
- ii) Enter the login credentials (i.e. User ID and password) which are mentioned in the e-mail received from KFinTech.

The E-Voting Event Number + Folio No. or DP ID Client ID will be your User ID. However, if you are already registered with KFinTech for e-voting, you can use your existing User ID and password for casting your vote. If required, please visit <https://evoting.kfintech.com> or contact Karvy at toll-free number 1800-309-4001 (from 9:00 a.m. to 6:00 p.m.) for your existing password.

- iii) After entering these details appropriately, click on "LOGIN".
- iv) You will now reach password change menu wherein you are required to mandatorily change your password. The new password shall comprise of minimum 8 characters with at least one upper case (A-Z), one lower case (a-z), one numeric value (0-9) and a special character (@, #, \$, etc.). The system will prompt you to change your password and update your contact details like mobile number, e-mail ID, etc. on first login. You may also enter a secret question and answer of your choice to retrieve your password in case you forget it. **It is strongly recommended that you do not share your password with any other person and that you take utmost care to keep your password confidential.**
- v) You need to login again with the new credentials.
- vi) On successful login, the system will prompt you to select the E-Voting event for Cohance Lifesciences Limited.
- vii) On the voting page, enter the number of shares (which represents the number of votes) as on the cut-off date under either 'FOR'/'AGAINST' or alternatively, you may partially enter any number under "FOR"/ "AGAINST", but the total number under 'FOR'/'AGAINST' taken together should not exceed your total shareholding as mentioned therein. You may also choose the

option 'ABSTAIN' and the shares held will not be counted under either head.

- viii) Members holding shares under multiple folios/demat accounts are requested to vote separately for each of their folios/demat accounts.
- ix) Voting has to be done for each item of this AGM Notice separately. In case you do not desire to cast your vote on any specific item, it will be treated as 'ABSTAINED'.
- x) You may then cast your vote by selecting an appropriate option and click on 'SUBMIT'.
- xi) A confirmation box will be displayed. Click 'OK' to confirm, else 'CANCEL' to modify. Once you confirm, you will not be allowed to modify your vote.
- xii) Corporate/ Institutional Members (i.e. other than Individuals, HUFs, NRIs, etc.) are also required to send legible scanned certified true copy (in PDF Format) of the Board Resolution/ Power of Attorney/ Authority Letter, etc., together with attested specimen signature(s) of the duly authorised representative(s), to the Scrutinizer at e-mail id: prenukaacs@gmail.com with a copy marked to evoting@kfintech.com. It is also requested to upload the same in the e-voting module in their login page. The scanned image of the above-mentioned documents should be in the naming format "Corporate Name_EVENT NO."

B. Procedure for Registration of email and Mobile: securities in physical mode

Physical shareholders are hereby notified that based on SEBI Master Circular number: SEBI/HO/MIRSD/POD-1/P/CIR/2024/37, dated May 07, 2024, All holders of physical securities in listed companies shall register the postal address with PIN for their corresponding folio numbers. It shall be mandatory for the security holders to provide mobile number. Moreover, to avail online services, the security holders can register e-mail ID. Holder can register/update the contact details through submitting the requisite ISR 1 form along with the supporting documents.

ISR 1 Form can be obtained by following the link:
<https://ris.kfintech.com/clientservices/isc/default.aspx>

ISR Form(s) and the supporting documents can be provided by any one of the following modes.

- a) Through 'In Person Verification' (IPV): the authorized person of the RTA shall verify the original documents furnished by the investor and retain copy(ies) with IPV stamping with date and initials; or
- b) Through hard copies which are self-attested, which can be shared on the address below;

| | |
|----------------|---|
| Name | KFIN Technologies Limited |
| Address | Selenium Building, Tower-B, Plot No 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddy, Telangana India - 500032. |

c) Through electronic mode with e-sign by following the link: <https://ris.kfintech.com/clientservices/isc/default.aspx#>

Detailed FAQ can be found on the link:
<https://ris.kfintech.com/faq.html>

For more information on updating the email and Mobile details for securities held in electronic mode, please reach out to the respective DP(s), where the DEMAT a/c is being held.

C. Members are requested to note the following contact details for addressing e-voting grievances:

Mrs. C. Shobha Ananda, Vice President
KFin Technologies Limited
Selenium Tower B, Plot 31-32, Gachibowli,
Financial District,
Nanakramguda, Hyderabad 500 032
Phone No.: +91 40 6716 2222 Toll-free No.:
1800-309-4001
E-mail: evoting@kfintech.com

| Procedure to login through websites of Depositories | |
|--|---|
| NSDL | CDSL |
| <p>(A) User already registered for IDeAS e-Services facility of NSDL may follow the following procedure:</p> <ol style="list-style-type: none"> (1) URL: https://eservices.nsdl.com (2) Click on the "Beneficial Owner" icon under 'IDeAS' section. (3) On the new page, enter existing User ID and Password. Post successful authentication, click on "Access to e-voting". (4) Click on company name or e-voting service provider and you will be re-directed to e-Voting service provider website for casting the vote during the remote e-voting period. | <p>(A) Existing user who have opted for Easi / Easiest of CDSL may follow the following procedure:</p> <ol style="list-style-type: none"> (1) URL: https://web.cdslindia.com/myeasitoken/home/login Or home/ login Or URL: www.cdslindia.com (2) Click on New System Myeasi. (3) Login with user id and password. (4) Option will be made available to reach e-voting page without any further authentication. (5) Click on e-voting service provider name to cast your vote. |
| <p>(B) User not registered for IDeAS e-Services facility of NSDL may follow the following procedure:</p> <ol style="list-style-type: none"> (1) To register click on link : https://eservices.nsdl.com (Select "Register Online for IDeAS") or https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp (2) Proceed with completing the required fields. (3) Post registration is completed, follow the process as stated in point no.1 above. | <p>(B) User not registered for Easi/Easiest may follow the following procedure:</p> <ol style="list-style-type: none"> (1) Option to register is available at https://web.cdslindia.com/myeasitoken/Registration/EasiRegistration (2) Proceed with completing the required fields. (3) Post registration is completed, follow the process as stated in point no.1 above. |

| Procedure to login through websites of Depositories | |
|--|---|
| NSDL | CDSL |
| (B) First time users can visit the e-Voting website directly and follow the process below: <ol style="list-style-type: none"> (1) URL: https://www.evoting.nsdl.com/ (2) Click on the icon "Login" which is available under 'Shareholder / Member' section. (3) Enter User ID (i.e. 16-digit demat account number held with NSDL), Password / OTP and a Verification Code as shown on the screen. (4) Post successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. (5) Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period. | (A) First time users can visit the e-Voting website directly and follow the process below: <ol style="list-style-type: none"> (1) URL: www.cdslindia.com (2) Provide demat Account Number and PAN No. (3) System will authenticate user by sending OTP on registered Mobile & Email as recorded in the demat Account. (4) After successful authentication, user will be provided links for the respective ESP where the e- Voting is in progress. (5) Click on company name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period. |

The instructions for remote e-voting are as under for Individual Shareholders holding shares in demat mode:

As per the SEBI circular No. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in Demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Individual Shareholder login through their Demat accounts/Website of Depository Participant

- You can also login using the login credentials of your demat account through your DP registered with NSDL /CDSL for e-Voting facility.
- Once logged-in, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL / CDSL Depository site after successful authentication, wherein you can see e-Voting feature.
- Click on options available against company name or e-Voting service provider – Kfintech and you will be redirected to e-Voting website of Kfintech for casting your vote during the remote e-Voting period without any further authentication.

Members who are unable to retrieve User ID / Password are advised to use "Forgot User ID" / "Forgot Password" options available on the websites of Depositories / Depository Participants.

| Contact details in case of any technical issue on NSDL Website | Contact details in case of any technical issue on CDSL Website |
|--|---|
| Members facing any technical issue in login can contact NSDL helpdesk by sending a request at evoting@nsdl.co.in or call at toll free no.: 1800 1020 990 and 1800 22 44 30 | Members facing any technical issue in login can contact CDSL helpdesk by sending a request at helpdesk.evoting@cdslindia.com or contact at 022-23058738 or 22-23058542/ 43. |

- The voting rights of Members / beneficial owners (in case of electronic shareholding) shall be in proportion to their shares in the paid-up equity share capital of the Company as on the cut-off date. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories as on the cut-off date only shall be entitled to avail the facility of voting, either through remote e-voting or e-voting at the AGM through Insta Poll.**

Facility to cast vote through Insta Poll will be made available on the Video Conferencing screen and will be activated once the Insta Poll is announced at the Meeting.

- ii) Any person who acquires shares of the company and becomes a member of the company after the sending of the AGM Notice and holds shares as on the cut-off date, i.e September 12, 2025, may obtain the login Id and password by sending a request at evoting@kfintech.com. However, if you are already registered with "KFinTech" for remote e-voting then you can use your existing user ID and password for casting your vote. If you have forgotten your password, you may reset your password by using "Forgot User Details/ Password" option available on <http://evoting.kfintech.com>.
- iii) The Board of Directors of the Company has appointed, Smt. D. Renuka, a Practicing Company Secretary (Membership No. A11963), as Scrutinizer to scrutinize the remote e-voting and Insta Poll process for AGM in a fair and transparent manner and she has communicated her willingness to be appointed and will be available for the said purpose.
- iv) The Scrutinizer will, after the conclusion of e-voting at the Meeting, scrutinise the votes cast at the Meeting (Insta Poll) and votes cast through remote e-voting, make a consolidated Scrutiniser's Report and submit the same to the Chairman or any person authorised by the Chairman after completion of the scrutiny of the votes cast through remote evoting before/ during the AGM. The results of e-voting will be declared within two working days of the conclusion of the Meeting and the same, along with the consolidated Scrutiniser's Report, will be placed on the website of the Company: www.suvenpharm.com and on the website of KFinTech at: <https://evoting.kfintech.com>. The result will simultaneously be communicated to the Stock Exchanges.
- v) Subject to receipt of requisite number of votes, the Resolutions proposed in the Notice shall be deemed to be passed on the date of meeting, i.e. September 19, 2025.

Date: June 26, 2025

Place: Hyderabad

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai-400093, Maharashtra, India

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSILC, Raidurg, Hyderabad - 500081 Telangana, India

CIN: L24299MH2018PLC422236

Email: investorservices@suvenpharm.com

Website: <https://www.suvenpharm.com>

By order of the Board of Directors
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Sd/-
Kundan Kumar Jha
Company Secretary, Compliance Officer
and Head - Legal
Membership No. A17612

EXPLANATORY STATEMENT TO NOTICE OF 7TH AGM

Statement pursuant to Section 102 of the Companies Act, 2013 ("Act") read with the rules made thereunder, as applicable, the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") and the Secretarial Standard on General Meetings ("SS-2")

Item No. 2 and 3

Dr. V Prasada Raju was appointed as Managing Director of the Company, by the members at the 5th Annual General Meeting ("AGM") of the Company held on December 15, 2023, for a period of five (5) years with effect from September 29, 2023, liable to retire by rotation. Dr. Prasada did not receive any remuneration from the Company. He was also serving as the Managing Director of erstwhile Cohance Lifesciences Limited, which merged with the Company effective from May 1, 2025, and was drawing remuneration from that company.

Pursuant to the Scheme of Amalgamation approved by the Hon'ble National Company Law Tribunal, Mumbai Bench, vide order dated March 27, 2025, erstwhile Cohance Lifesciences Limited has been amalgamated with the Company, effective date from May 1, 2025. Therefore, Dr. V Prasada Raju ceased to be the Managing Director of erstwhile Cohance Lifesciences Limited effective from May 1, 2025..

The Board of Directors of the Company at its meeting held on May 28, 2025, on the recommendation of the Nomination and Remuneration Committee, has approved the remuneration

to Dr. V Prasada Raju, with effect from May 1, 2025, subject to approval of the shareholders of the Company. The details of such remuneration are as hereunder:

| | | |
|--------------------------------|---|-------------------------------------|
| Fixed pay | : | ₹ 4,60,22,388 per annum |
| Variable pay | : | ₹ 87,42,096 per annum |
| Other benefits and perquisites | : | As per applicable Company's policy. |

This is the same remuneration drawn by Dr. Prasada in his capacity as the Managing Director of erstwhile Cohance Lifesciences Limited prior to the said merger.

Dr. V Prasada Raju devote his whole time and attention to the business of the Company and perform such duties as may be entrusted to him by the Board from time to time and separately communicated to him and exercise such powers as may be assigned to him, subject to the superintendence, control and directions of the Board in connection with and in the best interests of the business of the Company and the business of one or more of its subsidiaries and/ or associated companies, including performing duties as assigned to him from time to time by serving on the Boards of such subsidiaries and/ or associated companies or any other executive body or any committee of such a Company.

Additional information of Dr. V Prasada Raju pursuant to Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standard-2 are given below:

| | |
|---|---|
| Name of the Director | Dr. V Prasada Raju |
| Director Identification Number (DIN) | 07267366 |
| Age | 51 years |
| Nationality | Indian |
| Date of appointment at current designation/ Date of first appointment on the Board | Date of appointment: September 29, 2023 |
| Qualifications | PhD in Chemistry, PG Dip in Patents Law |
| Expertise in specific functional area | Dr. V Prasada Raju has 31+ years of techno-commercial experience in the pharma industry across the value chain, having held various leadership roles including at Granules India Limited and Dr. Reddy's Laboratories Limited. Dr. V Prasada Raju served as the Managing Director/ Whole-time Director of Cohance Lifesciences Limited for the period from October, 2020 to April, 2025. |

| | | | | | | | |
|---|---|-----------|---------------------------|--------------|------------------------|--------------------------------|--------------------------------------|
| Expertise in specific functional area (Contd.) | Dr. V Prasada Raju served as an Executive Director at Granules India Limited between 2012 and 2019, and was responsible for driving growth strategy, product portfolio, scientific affairs, regulatory affairs, intellectual property and new business initiatives. During his time at Granules India Limited, Dr. Prasada also led and built R&D and Greenfield projects. Dr. V Prasada Raju has also served on the Boards of Granules Omnichem Pvt Limited (Vizag, India), Granules Pharmaceuticals Inc., (DC, USA) and US Pharma Limited (FL, USA). | | | | | | |
| Date of first appointment | Appointed as the Managing Director for a period of five years w.e.f. from September 29, 2023. | | | | | | |
| Number of shares held in the Company including shareholding as a beneficial owner | 7,13,259 equity shares of ₹1 each | | | | | | |
| Directorship in other companies | He is Non-executive Director in Sapala Organics Private Limited, a subsidiary of the Company | | | | | | |
| Membership(s)/ Chairmanship(s) of Board Committees of other companies | Nil | | | | | | |
| Listed entities from which the Director has resigned in the past three years | Nil | | | | | | |
| Relationship with other Directors, Managers and Key Managerial Personnel of the Company | Dr. Prasada is not related to any Director or Key Managerial Personnel of the Company. | | | | | | |
| Number of Board meetings attended | Nine (9) | | | | | | |
| Terms of appointment along with details of remuneration sought to be paid and the remuneration last drawn by such person, if applicable | Term: Appointed as Managing Director for a term of five (5) years with effect from September 29, 2023 to September 28, 2028, by the shareholders of the Company at the 5 th AGM on December 15, 2023. Remuneration last drawn: Dr. Prasada had opted not to draw remuneration from the Company. He was receiving remuneration from erstwhile Cohance Lifesciences Limited, which merged with the Company with effect from May 1, 2025. He was entitled to receive following remuneration from erstwhile Cohance: <table border="1"> <tr> <td>Fixed pay</td><td>: ₹ 4,60,22,388 per annum</td></tr> <tr> <td>Variable pay</td><td>: ₹87,42,096 per annum</td></tr> <tr> <td>Other benefits and perquisites</td><td>: As per applicable Company's policy</td></tr> </table> Remuneration sought to be paid: As mentioned above. | Fixed pay | : ₹ 4,60,22,388 per annum | Variable pay | : ₹87,42,096 per annum | Other benefits and perquisites | : As per applicable Company's policy |
| Fixed pay | : ₹ 4,60,22,388 per annum | | | | | | |
| Variable pay | : ₹87,42,096 per annum | | | | | | |
| Other benefits and perquisites | : As per applicable Company's policy | | | | | | |

Pursuant to the provisions of Sections 196, 197, 203 and other applicable provisions, if any, read with Schedule V of the Companies Act, 2013 ("Act") as amended from time to time, the terms of remuneration of Dr. V Prasada Raju as specified above is now being placed before the Members for approval.

In terms of Section 152 of the Act, the term of office of Dr. V Prasada Raju, is subject to retirement by rotation at the ensuing 7th AGM, and being eligible, seeks re-appointment. Based on the annual performance evaluation carried out by the Board, the Board has recommended his appointment for approval of the members.

The Board recommends the Ordinary Resolution set out at Item Nos. 2 and 3 of the accompanying Notice for approval by the Members of the Company.

Except Dr. V Prasada Raju and his relatives, none of the other Directors or Key Managerial Personnel of the Company and their relatives are, in any way, concerned or interested, financially or otherwise, in the resolution set out at Item No. 2 and 3 of this Notice.

Item No. 4: Appointment of M/s Makarand M. Joshi & Co., practising Company Secretaries as Secretarial Auditors of the Company

In terms of the provisions of Section 204 of the Companies Act, 2013 (the "Act"), read with rules made thereunder, and Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the "SEBI Listing Regulations"), and other applicable provisions, every listed Company and certain other prescribed categories of companies

are required to annex a Secretarial Audit Report, issued by a Practicing Company Secretary, to their Board's report, prepared under Section 134(3) of the Act. Further, pursuant to Regulation 24A of the SEBI Listing Regulations read with SEBI notification dated December 12, 2024, and other applicable provisions, shareholders' approval is required for appointment of Secretarial Auditors. Such Secretarial Auditor must be a peer reviewed Company Secretary from the Institute of Company Secretaries of India (ICSI) and should not have incurred any of the disqualifications as specified by SEBI. The maximum tenure of the Secretarial Auditor in case it is a firm shall not be for not more than two (2) terms of five (5) consecutive years.

The Board of Directors of the Company at its meeting held on June 26, 2025, on the recommendation of the Audit Committee, and after considering the experience, market standing, competency of the audit team and independence, has approved the appointment of M/s. Makarand M. Joshi & Co., practicing Company Secretaries (Firm Regn. no: P2009MH007000), as Secretarial Auditors of the Company for a term of five (5) consecutive years, commencing from the financial year 2025-26 till financial year 2029-30, subject to approval of the shareholders at the Annual General Meeting ("AGM") of the Company.

M/s. Makarand M. Joshi & Co., is one of the leading firm of practicing Company Secretaries (hereinafter referred to as "MMJC") with over 25 years of experience in delivering comprehensive professional services across Corporate & Securities Laws, SEBI Regulations and FEMA Regulations. Their expertise includes conducting secretarial audits, due diligence audits, compliance audits, etc.

MMJC has given their consent to act as Secretarial Auditors of the Company and confirmed that their aforesaid appointment, if approved at the AGM, would be within the limits specified by the Institute of Company Secretaries of India. Furthermore, in terms of the amended regulations, MMJC has confirmed that they have subjected themselves to the peer review process of

the Institute of Company Secretaries of India and hold a valid peer review certificate.

The proposed remuneration to be paid to MMJC for secretarial audit services for the financial year ending March 31, 2026, is ₹3 Lakhs (Rupees three Lakhs only) plus applicable taxes and out-of-pocket expenses. The proposed fee is exclusive of costs for other permitted services which could be availed by the Company from MMJC. Besides the secretarial audit services, the Company may also obtain certifications from MMJC under various statutory regulations and certifications, as may be required by authorities, audit related services and other permissible non-secretarial audit services as required from time to time, for which they will be remunerated separately on mutually agreed terms, as approved by the Board of Directors in consultation with the Audit Committee. The Board of Directors and the Audit Committee may also approve revisions to the remuneration of MMJC for the remaining part of the tenure.

The Board of Directors, in consultation with the Audit Committee, may alter and vary the terms and conditions of appointment, including remuneration, in such manner and to such extent as may be mutually agreed with MMJC.

Based on the recommendations of the Audit Committee, the Board of Directors have approved and recommended the aforesaid proposal for approval of members taking into account the eligibility of the firm's qualification, independence, experience, and assessment as well as expertise of the partners and competency of the audit team in providing secretarial audit related services.

None of the Directors and Key Managerial Personnel of the Company and their respective relatives are concerned or interested, financially or otherwise, in passing the proposed Resolution.

The Board recommends the resolution set forth in item no. 4 for the approval of members.

Date: June 26, 2025

Place: Hyderabad

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai-400093, Maharashtra, India

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081 Telangana, India

CIN: L24299MH2018PLC422236

Email: investorservices@suvphenarm.com

Website: <https://www.suvphenarm.com>

By order of the Board of Directors
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Sd/-
Kundan Kumar Jha
Company Secretary, Compliance Officer
and Head - Legal
Membership No. A17612